Eiger BioPharmaceuticals, Inc.
Eiger BioPharmaceuticals, Inc. (EIGRQ) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
eigrq · pe ratio · data through Dec 31, 2023
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Eiger BioPharmaceuticals, Inc. (EIGRQ) measures how much investors pay for each dollar of the company's trailing earnings. EIGRQ's current PE ratio of N/A is calculated by dividing its stock price of $8.50 by its TTM earnings per share of -$50.78.
Source: FMP · /ratios-ttm · /analyst-estimates · 2023-12-31
PE Ratio History
2016 – 2023 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Eiger BioPharmaceuticals, Inc.You EIGRQ | $13M | N/A | — | -$50.78 |
 Avecho Biotechnology Limited AVEFF | $11M | N/A | — | -$0.00 |
 Bionomics Limited BNOEF | $9M | N/A | — | -$1898.63 |
 Ceapro Inc. CRPOF | $13M | N/A | — | -$0.06 |
 Living Cell Technologies Limited LVCLY | $11M | N/A | — | -$0.01 |
 MGC Pharmaceuticals Limited MGCLF | $12M | N/A | — | -$7.07 |
 Noxopharm Limited NOXOF | $15M | N/A | — | -$0.01 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2023-12-31Latest FY2023 | — | $-50.78 | — | |
2022-12-31 FY2022 | — | $-69.74 | — | |
2021-12-31 FY2021 | — | $-29.98 | — | |
2020-12-31 FY2020 | — | $-69.34 | — | |
2019-12-31 FY2019 | — | $-92.50 | — | |
2018-12-31 FY2018 | — | $-114.63 | — | |
2017-12-31 FY2017 | — | $-145.90 | — | |
2016-12-31 FY2016 | — | $-235.16 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Eiger BioPharmaceuticals, Inc. (EIGRQ) measures how much investors pay for each dollar of the company's trailing earnings. EIGRQ's current PE ratio of N/A is calculated by dividing its stock price of $8.50 by its TTM earnings per share of -$50.78.
Frequently asked questions
EIGRQ pe ratio · 6 questionsEIGRQ's current PE ratio is N/A as of 2026-06-09, based on a stock price of $8.50 and TTM EPS of -$50.78. Data sourced from Financial Modeling Prep via EIGRQ's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Eiger BioPharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09